Chemistry:DA-1241
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H31F2N5O2 |
| Molar mass | 471.553 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
DA-1241 is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.[1][2][3][4]
References
- ↑ Lee, Seung-Ho; Park, Hansu; Yang, Eun-Kyoung; Lee, Bo Ram; Jung, Il-Hoon; Kim, Tae-Hyoung; Goo, Moon Jung; Chae, Yuna et al. (October 2023). "GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling". Biomedicine & Pharmacotherapy 166: 115345. doi:10.1016/j.biopha.2023.115345. PMID 37657264.
- ↑ Kim, Mi-Kyung; Cheong, Ye Hwang; Lee, Seung Ho; Kim, Tae Hyoung; Jung, Il Hoon; Chae, Yuna; Lee, Jeong-Ha; Yang, Eun Kyoung et al. (December 2021). "A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression". Biomedicine & Pharmacotherapy 144: 112324. doi:10.1016/j.biopha.2021.112324.
- ↑ Kim, Mi-Kyung; Lee, Dae Young; Jeong, Jiyoon; Grimm, Michael; Franey, Bridgette B.; Hompesch, Marcus (1 June 2021). "766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)". Diabetes 70 (Supplement_1). doi:10.2337/db21-766-P.
- ↑ Kim, Youjin; Lee, Si Woo; Wang, Hyejin; Kim, Ryeong-Hyeon; Park, Hyun Ki; Lee, Hangkyu; Kang, Eun Seok (31 March 2022). "DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice". Diabetes & Metabolism Journal 46 (2): 337–348. doi:10.4093/dmj.2021.0056. PMID 35052026.
 |  |
